|
20.07.2016 16:30:00
|
Moody's: FDA Approval of Generic Nilandron is Credit Negative for Concordia; no change to rating or outlook
New York, July 20, 2016 -- Moody's Investors Service commented that the FDA approval of ANI Pharmaceuticals' (not rated) nilutamide tablets, a generic version of Nilandron, is credit negative for Concordia International Corp (B3 stable) as Concordia had the only FDA-approved version of the drug on the US market. No change to the company's B3 CFR rating or stable outlook.
Letzte Top-Ranking Nachrichten
Nachrichten
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.